ProCE Banner Activity

JADE MONO-2 Study Results: Efficacy and Safety of Abrocitinib in Patients With Moderate to Severe Atopic Dermatitis

Slideset Download
Conference Coverage
Moderate to severe atopic dermatitis was significantly improved for adolescents and adults treated with abrocitinib vs placebo.

Released: July 20, 2020

Expiration: July 19, 2021

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

This educational activity is supported by educational grants from

AbbVie Inc.

Pfizer, Inc.